Naoki Matsuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Naoki Matsuda has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Hirotaka Shibata
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine Oita University Yufu Japan
4 shared publications - Koro Gotoh
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan
3 shared publications - Satoshi Nagai
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu 879-5593, Japan
3 shared publications - Shotaro Miyamoto
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan
3 shared publications - Takayuki Masaki
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan
3 shared publications - Yoshinori Ozeki
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan
3 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Vol. 4 (8)
Parathyroid carcinoma diagnosed after pulmonary metastases 8 years after initial parathyroidectomy
Parathyroid carcinoma is a rare form of cancer. We describe a 45-year-old man diagnosed with parathyroid carcinoma long after initial surgery. At age 24, the patient had elevated serum calcium and intact parathyroid hormone (PTH). Ultrasonography revealed a left lower parathyroid tumor, which led to the diagnosis of primary hyperparathyroidism. Parathyroidectomy was performed, and the pathological diagnosis was parathyroid adenoma. At age 32, hypercalcemia and elevated intact PTH recurred, and computed tomography revealed a right lung tumor with focal uptake on 99mTc-methoxyisobutylisonitrile scintigraphy, which was clinically diagnosed as probable pulmonary metastasis from a parathyroid neoplasm; however, the patient declined further evaluation. At age 45, progressive hyperparathyroidism and enlargement of the right lung tumor were identified, leading to thoracoscopic resection. The resected tumor showed histopathological features similar to those of the previously resected parathyroid tumor. Immunohistochemistry revealed a low Ki-67 index but complete loss of nuclear parafibromin expression, confirming metastatic parathyroid carcinoma. Seven years after surgery, there was no evidence of recurrence or metastasis. Because it is often difficult to differentiate parathyroid carcinoma from parathyroid adenoma, and recurrence or metastasis may occur after a long interval, the possibility of carcinoma should always be considered and long-term follow-up is essential.
- 2 July 2026
- Vol. 4 (8)
Open AccessParathyroid carcinoma diagnosed after pulmonary metastases 8 years after initial parathyroidectomy
Parathyroid carcinoma is a rare form of cancer. We describe a 45-year-old man diagnosed with parathyroid carcinoma long after initial surgery. At age 24, the patient had elevated serum calcium and intact parathyroid hormone (PTH). Ultrasonography revealed a left lower parathyroid tumor, which led to the diagnosis of primary hyperparathyroidism. Parathyroidectomy was performed, and the pathological diagnosis was parathyroid adenoma. At age 32, hypercalcemia and elevated intact PTH recurred, and computed tomography revealed a right lung tumor with focal uptake on 99mTc-methoxyisobutylisonitrile scintigraphy, which was clinically diagnosed as probable pulmonary metastasis from a parathyroid neoplasm; however, the patient declined further evaluation. At age 45, progressive hyperparathyroidism and enlargement of the right lung tumor were identified, leading to thoracoscopic resection. The resected tumor showed histopathological features similar to those of the previously resected parathyroid tumor. Immunohistochemistry revealed a low Ki-67 index but complete loss of nuclear parafibromin expression, confirming metastatic parathyroid carcinoma. Seven years after surgery, there was no evidence of recurrence or metastasis. Because it is often difficult to differentiate parathyroid carcinoma from parathyroid adenoma, and recurrence or metastasis may occur after a long interval, the possibility of carcinoma should always be considered and long-term follow-up is essential.
- Open Access
Effects of Sleeve Gastrectomy on Blood Pressure Reduction in Diet-Induced Obese Hypertensive Rats: A Potential Role of Prouroguanylin
Background/Objectives: Sleeve gastrectomy (SG) is the most commonly performed bariatric surgery worldwide. It results in significant weight loss and improves metabolic disorders such as hypertension. Weight loss is thought to be the main factor contributing to blood pressure (BP) reduction after SG. Small-intestinal hormones may also mediate the antihypertensive effects of SG. We aimed to investigate the mechanisms underlying the antihypertensive effects of SG through small-intestinal hormones independently of weight loss. Methods: This study involved male Sprague–Dawley rats that underwent a sham operation or SG, followed by a dietary intervention involving a standard diet, a high-fat and high-salt diet, or pair-feeding with SG. Results: Three weeks postoperatively, SG significantly reduced systolic blood pressure (SBP) and increased urinary sodium excretion. RNA sequencing of the small intestine revealed upregulation of the gene encoding prouroguanylin (proUGN). proUGN is a small-intestinal hormone that inhibits renal sodium reabsorption by converting sodium/hydrogen ion exchanger type 3 (NHE3) in the proximal tubules into the inactive phosphorylated form at Ser552 (pS552-NHE3). Furthermore, SG significantly increased proUGN levels in the ileum and plasma, as well as the levels of pS552-NHE3 in the renal cortex. The administration of exogenous uroguanylin, which is converted from proUGN, resulted in increased renal pS552-NHE3, increased urinary sodium excretion, and decreased SBP without body weight reduction. These effects were similar to those observed with SG. Conclusions: SG increases proUGN secretion from the small intestine, leading to increased blood concentration. This inhibits NHE3 activity in the proximal tubules, promotes natriuresis and reduces BP.
Open AccessEffects of Sleeve Gastrectomy on Blood Pressure Reduction in Diet-Induced Obese Hypertensive Rats: A Potential Role of Prouroguanylin
Background/Objectives: Sleeve gastrectomy (SG) is the most commonly performed bariatric surgery worldwide. It results in significant weight loss and improves metabolic disorders such as hypertension. Weight loss is thought to be the main factor contributing to blood pressure (BP) reduction after SG. Small-intestinal hormones may also mediate the antihypertensive effects of SG. We aimed to investigate the mechanisms underlying the antihypertensive effects of SG through small-intestinal hormones independently of weight loss. Methods: This study involved male Sprague–Dawley rats that underwent a sham operation or SG, followed by a dietary intervention involving a standard diet, a high-fat and high-salt diet, or pair-feeding with SG. Results: Three weeks postoperatively, SG significantly reduced systolic blood pressure (SBP) and increased urinary sodium excretion. RNA sequencing of the small intestine revealed upregulation of the gene encoding prouroguanylin (proUGN). proUGN is a small-intestinal hormone that inhibits renal sodium reabsorption by converting sodium/hydrogen ion exchanger type 3 (NHE3) in the proximal tubules into the inactive phosphorylated form at Ser552 (pS552-NHE3). Furthermore, SG significantly increased proUGN levels in the ileum and plasma, as well as the levels of pS552-NHE3 in the renal cortex. The administration of exogenous uroguanylin, which is converted from proUGN, resulted in increased renal pS552-NHE3, increased urinary sodium excretion, and decreased SBP without body weight reduction. These effects were similar to those observed with SG. Conclusions: SG increases proUGN secretion from the small intestine, leading to increased blood concentration. This inhibits NHE3 activity in the proximal tubules, promotes natriuresis and reduces BP.
- Open Access
- 30 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5294
Effects of Sleeve Gastrectomy and Treadmill Exercise on Skeletal Muscle and Ectopic Fat in High-Fat Diet-Induced Obese Rats
A high-fat diet (HFD) can lead to obesity and skeletal muscle atrophy. Sleeve gastrectomy (SG) improves obesity and increases skeletal muscle mass. This study examined whether SG prevented skeletal muscle atrophy in a diet-induced rat obesity rat model. First, 8-week-old male Sprague-Dawley rats underwent surgical (sham-operated or SG) and dietary (standard, high-fat diet, or same pair feeding as SG [PF]) interventions without exercise. In the second experiment, treadmill exercise was added for 4 weeks post-SG (SG + Ex). In the third experiment, rats received an adiponectin receptor agonist (AdipoRon) injection. The HFD induced weight gain and decreased muscle fiber area. SG + Ex reversed these levels, followed by increases in adiponectin in the blood and skeletal muscle and myoblast determination protein 1 (MyoD) and decreased peri-muscular adipose tissue (PMAT) mass, but SG alone did not. No similar changes were observed in the PF group, with or without exercise. Injection of AdipoRon had a similar effect on skeletal muscle and PMAT as SG + Ex. The combination of SG and exercise, but not calorie restriction alone, had better impacts on skeletal muscle and PMAT than SG or exercise alone.
- 30 May 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (11) , 5294
Open AccessEffects of Sleeve Gastrectomy and Treadmill Exercise on Skeletal Muscle and Ectopic Fat in High-Fat Diet-Induced Obese Rats
A high-fat diet (HFD) can lead to obesity and skeletal muscle atrophy. Sleeve gastrectomy (SG) improves obesity and increases skeletal muscle mass. This study examined whether SG prevented skeletal muscle atrophy in a diet-induced rat obesity rat model. First, 8-week-old male Sprague-Dawley rats underwent surgical (sham-operated or SG) and dietary (standard, high-fat diet, or same pair feeding as SG [PF]) interventions without exercise. In the second experiment, treadmill exercise was added for 4 weeks post-SG (SG + Ex). In the third experiment, rats received an adiponectin receptor agonist (AdipoRon) injection. The HFD induced weight gain and decreased muscle fiber area. SG + Ex reversed these levels, followed by increases in adiponectin in the blood and skeletal muscle and myoblast determination protein 1 (MyoD) and decreased peri-muscular adipose tissue (PMAT) mass, but SG alone did not. No similar changes were observed in the PF group, with or without exercise. Injection of AdipoRon had a similar effect on skeletal muscle and PMAT as SG + Ex. The combination of SG and exercise, but not calorie restriction alone, had better impacts on skeletal muscle and PMAT than SG or exercise alone.
- Open Access
- 4 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 433
Development of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations
In the present study, we developed a new chemiluminescent enzyme immunoassay (CLEIA) using a two-step sandwich method to measure aldosterone concentrations. We investigated serum and plasma aldosterone concentrations in 75 blood samples from 27 patients using a radioimmunoassay (RIA) and the CLEIA (with current and newly improved reagents) as well as liquid chromatography-tandem mass spectrometry (LC-MS/MS). Based on the results of the Passing–Bablok regression analysis, the aldosterone levels measured using CLEIA with the new reagents and those measured by LC-MS/MS were found to be significantly correlated (slope, 0.984; intercept, 0.2). However, aldosterone levels varied depending on the measurement method (i.e., CLEIA with the new reagent, CLEIA with the current reagent, and RIA). Aldosterone levels were lower with the improved CLEIA method than with RIA and CLEIA using the current reagent. Therefore, the cutoff values of the screening test as well as those of the confirmatory test for primary aldosteronism (PA) should be adjusted to follow current clinical practice guidelines for PA. The formula that can be used to obtain the aldosterone level (pg/mL) when using CLEIA with the new reagent is 0.765 × RIA (pg/mL) − 33.7. This formula will enable PA cutoff values to be set for provisional screening and confirmatory tests.
- 4 March 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 433
Open AccessDevelopment of a New Chemiluminescent Enzyme Immunoassay Using a Two-Step Sandwich Method for Measuring Aldosterone Concentrations
In the present study, we developed a new chemiluminescent enzyme immunoassay (CLEIA) using a two-step sandwich method to measure aldosterone concentrations. We investigated serum and plasma aldosterone concentrations in 75 blood samples from 27 patients using a radioimmunoassay (RIA) and the CLEIA (with current and newly improved reagents) as well as liquid chromatography-tandem mass spectrometry (LC-MS/MS). Based on the results of the Passing–Bablok regression analysis, the aldosterone levels measured using CLEIA with the new reagents and those measured by LC-MS/MS were found to be significantly correlated (slope, 0.984; intercept, 0.2). However, aldosterone levels varied depending on the measurement method (i.e., CLEIA with the new reagent, CLEIA with the current reagent, and RIA). Aldosterone levels were lower with the improved CLEIA method than with RIA and CLEIA using the current reagent. Therefore, the cutoff values of the screening test as well as those of the confirmatory test for primary aldosteronism (PA) should be adjusted to follow current clinical practice guidelines for PA. The formula that can be used to obtain the aldosterone level (pg/mL) when using CLEIA with the new reagent is 0.765 × RIA (pg/mL) − 33.7. This formula will enable PA cutoff values to be set for provisional screening and confirmatory tests.